News coverage about Valeritas (NASDAQ:VLRX) has trended somewhat positive this week, according to Accern Sentiment Analysis. The research group identifies negative and positive news coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Valeritas earned a media sentiment score of 0.15 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 44.7551118740991 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Shares of NASDAQ VLRX traded down $0.12 during trading on Monday, reaching $1.61. 138,705 shares of the stock traded hands, compared to its average volume of 438,697. Valeritas has a 52-week low of $1.19 and a 52-week high of $7.20. The company has a debt-to-equity ratio of -2.57, a current ratio of 2.56 and a quick ratio of 1.80. The stock has a market capitalization of $38.74 million, a PE ratio of -0.19 and a beta of 4.32.
Valeritas (NASDAQ:VLRX) last issued its quarterly earnings data on Wednesday, May 9th. The company reported ($1.72) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.13) by $0.41. The business had revenue of $6.08 million for the quarter, compared to analysts’ expectations of $6.00 million. Valeritas had a negative return on equity of 1,768.69% and a negative net margin of 225.97%. equities analysts expect that Valeritas will post -6.67 EPS for the current fiscal year.
A number of research analysts have recently commented on the company. ValuEngine raised Valeritas from a “hold” rating to a “buy” rating in a research report on Saturday, June 2nd. Cowen cut Valeritas from an “outperform” rating to a “market perform” rating in a research report on Wednesday, March 28th.
In related news, insider John Edward Timberlake acquired 22,500 shares of the company’s stock in a transaction that occurred on Wednesday, April 25th. The shares were acquired at an average price of $1.67 per share, with a total value of $37,575.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Joseph M. Mandato acquired 20,000 shares of the company’s stock in a transaction that occurred on Thursday, May 10th. The shares were bought at an average cost of $1.63 per share, for a total transaction of $32,600.00. The disclosure for this purchase can be found here. Insiders have purchased a total of 47,500 shares of company stock worth $78,275 in the last three months. 1.20% of the stock is currently owned by insiders.
Valeritas Company Profile
Valeritas Holdings, Inc, a commercial-stage medical technology company, focuses on the development and commercialization of technologies to treat patients with Type 2 diabetes in the United States and China. It offers V-Go, a wearable insulin delivery device for basal-bolus therapy. The company also develops h-Patch, a controlled delivery technology platform; Mini-Ject technology for needle-free injection systems; and Micro-Trans technology for microneedle design, fabrication, and drug delivery.
Receive News & Ratings for Valeritas Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeritas and related companies with MarketBeat.com's FREE daily email newsletter.